

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
 (Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
 KPO-LTT-PI/LTT-85/

In Re Application Of: Ishihara, T.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/550,990	N/A	to be assigned	44702	1615	8274

Title: Intravenous nanoparticles for targeting drug delivery and sustained drug release

Address to:
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

37 CFR 1.97(b)

- The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

- The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

the statement specified in 37 CFR 1.97(e);

OR

the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
KPO-LTT-PI/LTT-85/

In Re Application of: Ishihara, T.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/550,990	N/A	to be assigned	44702	1615	8274

Title: Intravenous nanoparticles for targeting drug delivery and sustained drug release

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

A check in the amount of _____ is attached.
 The Director is hereby authorized to charge and credit Deposit Account No. 50-3195 _____ as described below.
 Charge the amount of _____
 Credit any overpayment.
 Charge any additional fee required.
 Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa)

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

March 28, 2006

(Date)

Signature

Signature of Person Mailing Correspondence

Manette Dennis

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Manette Dennis
Signature

Dated: March 28, 2006

Manette Dennis (Reg. No. 30,623)
Ostrager Chong Flaherty & Broitman P.C.
250 Park Avenue, Suite 825
New York, New York 10177-0899

CC: Dr. Osamu Kusama

Application Serial No. 10/550,990
Information Disclosure Statement – Additional Sheet

Sheet 2 of 3

Application Serial No. 10/550,990

Applicants: ISHIHARA, T

entitled: INTRAVENOUS NANOPARTICLES FOR TARGETING DRUG DELIVERY
AND SUSTAINED DRUG RELEASE

EP 1 398 025 A is the European regional application corresponding to WO 02/096396 A1. WO 02/096396 A1 is listed on the International Search Report for PCT/JP2004/003246 and was published on Dec. 5, 2002. EP 1 398 025 A1 is provided as an English equivalent to WO 02/096396 A1.

Japanese National Publication No. Hei 10-511957 is listed on page 1 of the application as filed. It is the Japanese National Phase application for International Application No. PCT/US96/00476. International Application No. PCT/US96/00476 was published as WO 96/20698, which is enclosed as a translation of Japanese National Publication No. Hei 10-511957.

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			
(Use as many sheets as necessary)			
Sheet	1	of	3
		Application Number 10/550,990	
		Filing Date N/A	
		First Named Inventor Ishihara, T.	
		Art Unit 1615	
		Examiner Name to be assigned	
		Attorney Docket Number KPO-LTT-P1/LTT-85/US	

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴				
d	EP	1 002 529	A1	05-24-2000	Takeda Chemical Industries	whole document	
c	EP	1 398 025	A1	03-17-2004	LTT Bio-Pharma Co., Ltd.	whole document	
18h	JP	8 217 091		08-27-1996	Takeda Chem Ind Ltd	whole document	✓
ation	JP	11-10 611 067		11-19-1998	Univ Michigan	whole document	✓
ad	JP	3002 242 306		12-02-2003	Mitsubishi K&K	whole document	✓

No	English	JP	8-2170951	88-27-1996	Takeda Chem Ind Ltd	whole document	✓
Translations	JP	116-10-5419957	91-18-1998	Omni Michigan	whole document	✓	

Examiner Signature /Paul Dickinson/ Date Considered 12/13/2007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **Applicant's unique citation designation number (optional).** See Kindia Codes of USPTO Patent Documents at uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Examiner's earliest document, the indication of the year of the issue of the Examiner's document, the serial number of the issued document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P-D/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		<i>Application Number</i>	10/550,990
		<i>Filing Date</i>	N/A
		<i>First Named Inventor</i>	Ishihara, T.
		<i>Art Unit</i>	1615
		<i>Examiner Name</i>	to be assigned
(Use as many sheets as necessary)			
Sheet	2	of	3
		Attorney Docket Number	KPO-I-TT-P1/L1/T-85/US

NON-PATENT LITERATURE DOCUMENTS

Examiner Signature	/Paul Dickinson/	Date Considered	12/13/2007
-----------------------	------------------	--------------------	------------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

1 Applicant's unique citation designation number (optional). **2** Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH /P.D./